QED

BridgeBio Pharma’s QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in Achondroplasia Data Accepted to ENDO 2020

on May 12, 2020
FEATURED

SAN FRANCISCO, May 11, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that in vitro and in vivo data from two studies support QED’s plans to evaluate a low dose of infigratinib as a treatment option for children with achondroplasia, the most common cause of disproportionate short stature.…

Read More
QED

QED COVID-19 Update

on March 27, 2020
FEATURED

Dear Chandler Project, We at QED know that this is a challenging time for all families. We hope that you are all doing well, are safe, and are using this time to ensure the safety and well-being of your loved ones.  We are actively assessing the impact that COVID-19 may…

Read More
QED

Study of Infigratinib in Children With Achondroplasia

on February 11, 2020
FEATURED

This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1-3-selective tyrosine kinase inhibitor, in children 3 to 11 years of age with Achondroplasia (ACH) who previously participated in the PROPEL study (Protocol QBGJ398-001) for…

Read More
QED

QED Achondroplasia Clinical Update

on December 20, 2019
FEATURED

QED Therapeutics, Inc. (“QED”), a subsidiary of BridgeBio Pharma, Inc. (“BridgeBio”) focuses on bringing medicine to people living with conditions that are caused by changes in fibroblast growth factor receptor (FGFR) genes. QED is developing a medicine which may improve the overall health and quality of life of people with…

Read More